FREE subscriptions for doctors and students... click here
You have 3 open access pages.
Cholesterol-lowering therapy is an area of medicine that has prompted heated debate and a great deal of confusion.
Hypercholesterolaemia treatment can be considered in terms of primary and secondary prevention of coronary heart disease.
In general, the treatment of choice for raised cholesterol is a statin.
NICE state that (1):
- before offering lipid modification therapy for primary
prevention, all other modifiable CVD risk factors should be considered and their
management optimised if possible. Baseline blood tests and clinical assessment
should be performed, and comorbidities and secondary causes of dyslipidaemia should
be treated. Assessment should include:
- smoking status
- alcohol consumption
- blood pressure
- body mass index or other measure of obesity
- fasting total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides (if fasting levels are not already available)
- fasting blood glucose
- renal function
- liver function (transaminases)
- thyroid-stimulating hormone (TSH) if dyslipidaemia is present
Reference:
Links:
- statin treatment
- trials with respect to treatment of hypercholesterolaemia
- hypercholesterolaemia - primary prevention
- hypercholesterolaemia - secondary prevention
- lipid-lowering diet
- lipid-lowering treatment in primary prevention
- hyperlipidaemia
- lipid lowering treatment for secondary prevention
- evidence in cardiac disease
- lipid lowering drugs